🇺🇸 United States Country × Condition
acute myeloid leukemia Clinical Trials in United States
Active clinical trials for acute myeloid leukemia with research sites in United States. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 20 // Recruiting: 20 Phases: Phase 1, Phase 2, Phase 1 // Updated: Daily
Total Trials
20
Recruiting Now
20
Country
🇺🇸 United States
Active Trials in United States (20)
NCT04065399 Phase 1, Phase 2
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Enrollment
447 pts
Country
🇺🇸 United States
Syndax Pharmaceuticals
View Trial → NCT05748197 Phase 1
Recruiting
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Enrollment
40 pts
Country
🇺🇸 United States
Memorial Sloan Kettering Cancer Cen...
View Trial → NCT07737769 Phase 1
Recruiting
Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
Enrollment
20 pts
Country
🇺🇸 United States
University of Michigan Rogel Cancer...
View Trial → NCT06448013 Phase 1
Recruiting
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
Enrollment
22 pts
Country
🇺🇸 United States
M.D. Anderson Cancer Center
View Trial → NCT05732103 Phase 1, Phase 2
Recruiting
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Enrollment
225 pts
Country
🇺🇸 United States
Chordia Therapeutics, Inc.
View Trial → NCT05955261 Phase 2
Recruiting
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
Enrollment
70 pts
Country
🇺🇸 United States
St. Jude Children's Research Hospit...
View Trial → NCT06543381 Phase 1
Recruiting
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Enrollment
15 pts
Country
🇺🇸 United States
City of Hope Medical Center
View Trial → NCT04771130 Phase 1, Phase 2
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
Enrollment
260 pts
Country
🇺🇸 United States
BeOne Medicines
View Trial → NCT06834282 Phase 1
Recruiting
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Enrollment
18 pts
Country
🇺🇸 United States
CERo Therapeutics Holdings, Inc.
View Trial → NCT07046078 Phase 2
Recruiting
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Enrollment
20 pts
Country
🇺🇸 United States
Fred Hutchinson Cancer Center
View Trial → NCT03471260 Phase 1, Phase 2
Recruiting
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Enrollment
96 pts
Country
🇺🇸 United States
M.D. Anderson Cancer Center
View Trial → NCT02508038 Phase 1
Recruiting
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Enrollment
22 pts
Country
🇺🇸 United States
University of Wisconsin, Madison
View Trial → NCT07437950 Phase 2
Recruiting
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Enrollment
126 pts
Country
🇺🇸 United States
National Cancer Institute (NCI)
View Trial → NCT04167696 Phase 1
Recruiting
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Enrollment
27 pts
Country
🇺🇸 United States
Celyad Oncology SA
View Trial → NCT06152809 Phase 1
Recruiting
CIML NK Cells With Venetoclax for AML
Enrollment
10 pts
Country
🇺🇸 United States
Dana-Farber Cancer Institute
View Trial → NCT06440135 Phase 1
Recruiting
Ziftomenib Maintenance Post Allo-HCT
Enrollment
22 pts
Country
🇺🇸 United States
Massachusetts General Hospital
View Trial → NCT06128070 Phase 2
Recruiting
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Enrollment
40 pts
Country
🇺🇸 United States
City of Hope Medical Center
View Trial → NCT04659616 Phase 1
Recruiting
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Enrollment
32 pts
Country
🇺🇸 United States
OHSU Knight Cancer Institute
View Trial → NCT06297551
Recruiting
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
Enrollment
20 pts
Country
🇺🇸 United States
Suhu Liu
View Trial → NCT03586609 Phase 2
Recruiting
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Enrollment
145 pts
Country
🇺🇸 United States
M.D. Anderson Cancer Center
View Trial → Frequently Asked Questions
How many acute myeloid leukemia clinical trials are active in United States?
There are currently 20 active clinical trials for acute myeloid leukemia with sites in United States, of which 20 are actively recruiting patients.
How can I join a acute myeloid leukemia clinical trial in United States?
To join a acute myeloid leukemia clinical trial in United States, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United States directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are acute myeloid leukemia trials in United States?
Active acute myeloid leukemia trials in United States span Phase 1, Phase 2, Phase 1, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology